{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:55:12Z","timestamp":1792162512217,"version":"4.4.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.euroneuro.2016.02.002","type":"journal-article","created":{"date-parts":[[2016,2,9]],"date-time":"2016-02-09T01:35:13Z","timestamp":1454981713000},"page":"717-728","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Changes in psychopathology in schizophrenia patients starting treatment with new-generation antipsychotics: therapeutic drug monitoring in a naturalistic treatment setting"],"prefix":"10.1016","volume":"26","author":[{"given":"Alexandra","family":"Kaufmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Wartelsteiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nursen","family":"Yalcin-Siedentopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Baumgartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falko","family":"Biedermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Edlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Kemmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Rettenbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja T.","family":"Rissanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian G.","family":"Widschwendter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Zernig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Wolfgang","family":"Fleischhacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2016.02.002_bib1","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1476-5381.1985.tb12941.x","article-title":"An operational model of pharmacological antagonism: the effect of E\/[A] curve shape on agonist dissociation constant estimation","volume":"84","author":"Black","year":"1985","journal-title":"Br. J. Phamacol."},{"key":"10.1016\/j.euroneuro.2016.02.002_bib2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00213-011-2319-z","article-title":"\u201cThere is no dose-response relationship in psychopharmacotherapy\u201d vs \u201cpharmacotherapy in psychiatry is based on ligand-receptor interaction\u201d: a unifying hypothesis and the need for plasma concentration based clinical trials","volume":"217","author":"Eggart","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2016.02.002_bib3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00004714-200106000-00010","article-title":"Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study","volume":"21","author":"Gaertner","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.02.002_bib4","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00115-013-3925-2","article-title":"Therapeutisches Drug-Monitoring in der Psychiatrie. Kurze Zusammenfassung des neuen Konsensupapiers der Arbeitsgruppe TDM der AGNP (Therapeutic drug monitoring in psychiatry: a brief summary of the new consensus paper by the task force on TDM of the AGNP)","volume":"85","author":"Grunder","year":"2014","journal-title":"Nervenarzt"},{"key":"10.1016\/j.euroneuro.2016.02.002_bib5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.euroneuro.2016.02.002_bib6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1017\/S0033291700050182","article-title":"A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity","volume":"13","author":"Hogan","year":"1983","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2016.02.002_bib7","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2016.02.002_bib8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2016.02.002_bib9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.02.002_bib10","first-page":"5","article-title":"Maintenance treatment with antipsychotic drugs for schizophrenia","author":"Leucht","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2016.02.002_bib11","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2016.02.002_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU Side Effect Rating Scale-a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2016.02.002_bib13","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.schres.2013.04.002","article-title":"Plasma levels of second-generation antipsychotics and clinical response in acute psychosis: a review of the literature","volume":"147","author":"Lopez","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2016.02.002_bib14","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/FTD.0b013e3181aa4780","article-title":"Serum levels of risperidone and its metabolite, 9-hydroxyrisperidone: correlation between drug concentration and clinical response","volume":"31","author":"Lostia","year":"2009","journal-title":"Ther. Drug Monit."},{"issue":"Suppl 5","key":"10.1016\/j.euroneuro.2016.02.002_bib15","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1111\/j.1528-1157.1995.tb06006.x","article-title":"Antiepileptic drug monitoring: a reappraisal","volume":"36","author":"Mattson","year":"1995","journal-title":"Epilepsia"},{"key":"10.1016\/j.euroneuro.2016.02.002_bib16","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s002130000576","article-title":"Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia","volume":"153","author":"Spina","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2016.02.002_bib17","first-page":"81","article-title":"Pharmacokinetic simulations for forensic toxicological evaluation and expertise","volume":"67","author":"Toennes","year":"2000","journal-title":"Toxichem. +Krimtech."},{"key":"10.1016\/j.euroneuro.2016.02.002_bib18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2165\/00003088-199834030-00005","article-title":"The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia","volume":"34","author":"Ulrich","year":"1998","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.euroneuro.2016.02.002_bib19","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/0269881107077357","article-title":"Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia","volume":"21","author":"Wang","year":"2007","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.02.002_bib20","first-page":"18","article-title":"Measuring adherence to medication in schizophrenia: the relationship between attitudes toward drug therapy and plasma levels of new-generation antipsychotics","author":"Yalcin-Siedentopf","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.02.002_bib21","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1177\/0269881109104849","article-title":"Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients","volume":"24","author":"Yasui-Furukori","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.02.002_bib22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/1056-8719(96)00053-6","article-title":"Calculation of agonist efficacy, apparent affinity and receptor population changes: comparison of different analytical approaches","volume":"35","author":"Zernig","year":"1996","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.euroneuro.2016.02.002_bib23","first-page":"57","article-title":"Empfehlungen f\u00fcr die gutachterliche Bewertung von Medikamentenspiegeln in der Psychiatrie im gerichtsanh\u00e4ngigen Schadensfall","volume":"2","author":"Zernig","year":"2009","journal-title":"Psychopharmakotherapie"},{"key":"10.1016\/j.euroneuro.2016.02.002_bib24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000103923","article-title":"Explaining the escalation of drug use in substance dependence: models and appropriate animal laboratory tests","volume":"80","author":"Zernig","year":"2007","journal-title":"Pharmacology"}],"updated-by":[{"DOI":"10.1016\/j.euroneuro.2019.12.108","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000}}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X16000389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X16000389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T11:33:06Z","timestamp":1617276786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X16000389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0924977X16000389"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2016.02.002","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.euroneuro.2019.12.108","asserted-by":"object"}]},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in psychopathology in schizophrenia patients starting treatment with new-generation antipsychotics: therapeutic drug monitoring in a naturalistic treatment setting","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2016.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}